Aggrenox belongs to the large medical class well-known as antiaggregants. This medicament is chiefly applied as secondary preventive measures of ischemic stroke or cerebral infarction (by mechanism of thrombosis) and transistorized ischemic attacks.
Coumadin is very effective remedy for treatment and prevention of blood vessels’ embolism and thrombosis: sharp venous thrombosis and embolism of pulmonary artery, postoperative thrombosis, repeated myocardial infarction, recurrent venous thrombosis, repeated embolism of pulmonary artery and several others.
Crestor covers to the hypolipidemic agents. This preparation is mostly taken as therapy of atherosclerosis for slowdown of illness progression by patients who have hypolipidemic (lipid lowering) treatment, as addition to diet (under mixed hypercholesterolemia) and so on.
Lovaza is mainly employed as supplementary remedy to the low fat and low cholesterol diet for lowering of triglycerides (TG) level by grown-up patients with heavy form of hypertriglyceridemia.
Niaspan is chiefly taken for lowering of the highest level of cholesterol and adipose tissues in blood. This can help to prevent some problems called by cholesterin and fat which brings to the blood vessels’ obstruction.
Pravachol belongs to the sclerous officinal remedies. Patients use this medication for lowering of general cholesterol’s heightened concentrations and cholesterin of low-density lipoproteins by sick persons with primary hypercholesterolemia (the highest content of cholesterol in blood).
Vytorin refers to the hypolipidemic drugs from the statines’ class. The medicament is taken under the primary hypercholesterolemia under the dietotherapy inefficiency, combined hypercholesterolemia and hypertriglyceridemia.
Zetia covers to the hypolipidemic or lipid lowering medical preparations. The remedy is recommended for lowering of sitosterol and kampesterol’s heightened level (homozygous sytosterolemia or fitosterolemia.
Zocor is lipid lowering or hypolipidemic medical agent. The medication is exhibited for risk diminishing of serious vascular and coronary aftereffects of some illnesses (unfatal cardiac infarction, coronary death, and stroke) and several others.